Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: Implications in designing antigen- presenting cell-based tumor vaccines

Journal of Immunology

Volumn 162, Issue 9, 1999, Pages 5576-5583

  Chakraborty, Nitya G ^a,b   Li, Li ^a   Sporn, Jonathan R ^a   Kurtzman, Scott H ^a   Ergin, M T ^a   Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR VACCINE;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNOREGULATION; LYMPHOCYTE COUNT; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HUMANS; IMMUNE SERA; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 0033136779     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Banchereau, J., and R. M Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
2. Zitvogel, L., J. L. Mayordomo, T. Tjandrawan, A. B. DeLeo, MR. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells, B7 co-stimulation and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
3. Paglia, P., C. Chiodini, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
4. Celluizi, C. M., J. L. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL mediated protective tumor immunity. J. Exp. Med. 183:283.
5. Boon, T., and P. Van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
6. Young, J. W., and K. Inaba. 1996. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted anti-tumor immunity. J. Exp. Med. 183:7.
7. Mukherji, B., N. G. Chakraborty, S. Yamasaki, T. Okino, H. Yamase, J. R. Sporn, S. H. Kurtzman, M. T. Ergin, J. Ozols, J. Meehan, and F. Mauri. 1995. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 92:8078.
8. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
9. Nestle, F. O., S. Alijagic, M. Gilliiet, Y. Sun, S. Grable, S. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
10. Chakraborty, N. G., J. R. Sporn, A. E. Tortora, S. H. Kurtzman, H. Yamase, M. T. Ergin, and B. Mukherji. 1998. Immunization with a tumor cell lysate-loaded autologous antigen presenting cell-based vaccine in melanoma. Cancer Immunol. Immunother. 47:58.
11. Mukherji, B., A. Guha, N. G. Chakraborty, M. Sivanandham, A. Nashed, J. R. Sporn, and M. T. Ergin. 1989. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J. Exp. Med. 169:1961.
12. Yamasaki, S., T. Okino, N. G. Chakraborty, O. A. Adkisson, A. Sampieri, S. J. Padula, F. Mauri, and B. Mukherji. 1995. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating factor cultured macrophages from HLA-A1 melanoma patients. Cancer Immunol. Immunother. 40:268.
13. + T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res. 58:5305.
14. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749.
15. Marchand, M., E. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, J. L. Canon, C. Laurent, J. M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jaeger, F. Brassue, J. Herman, P. G. Coulie, and T. Boon. 1995. Tumor regression response in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63:883.
16. Jaeger, E., H. Bernhard, P. Romero, M. Ringhoffer, M. Arand, J. Karbach, C. IlsemAnn, M. Hagedorn, and A. Knuth. 1996. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66:162.
17. Rosenberg, S. A., J. C. Yang, H. P. Schwartzentruber, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. R. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn, and D. E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
18. Schwartz, R. H., D. L. Mueler, M. K. Jenkins, and H. Quill. 1989. T-cell clonal anergy. Cold Spring Harbor Symp. Quant. Biol. 56:605.
19. Moskophidis, D., F. Lechner, H. Pircher, and R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758.
20. Ohasi, P. H., K. Oehen, H. P. Burki, T. Pircher, B. Ohasi, B. Odermatt, B. Malissen, R. M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in virus antigen transgenic mice. Cell 65:305.
21. Oldstone, M. B. A., M. Nerenberg, P. Southern, J. Proce, and H. Lewicki. 1991. Virus infection triggers insulin-independent diabetes mellitus in transgenic model: role of anti-self (virus) immune response. Cell 65:319.
22. Strand, S., W. J. Hoffmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Gale. 1996. Lymphocytes apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat. Med. 2:1363.
23. Mossmann, T. R., and S. Sad. 1996. The expanding universe of T cell subsets: Th1, Th2 and more. Immunol. Today 17:138.
24. Scott, P., P. Natovitz, R. Coffman, E. Pearce, and A. Sher. 1988. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasitic antigens. J. Exp. Med. 168:1675.
25. Chakraborty, N. G., D. R. Twarzik, M. Sivanandham, M. T. Ergin, K. E. Hellström, and B. Mukherji. 1990. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J. Immunol. 145:2359.
26. Chakraborty, N. G., J. R. Sporn, D. R. Pasquale, M. T. Ergin, and B. Mukherji. 1991. Suppression of lymphokine-activated killer cell generation by tumor infiltrating lymphocytes. Clin. Immunol. Immunopathol. 59:407.
27. Ding, L., and E. N. Shevach. 1992. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J. Immunol. 148:3133.
28. Giovarelli, M., P. Musiani, A. Modesti, P. Dellabona, G. Casorati, A. Allione, M. Cansalvo, F.di Pierro, C. De Giovani, T. Musso, and G. Forni. 1995. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol. 155:3112.
29. Kundu, N., and A. M. Fulton. 1997. Interleukin-10 inhibits tumor metastasis, down regulates MHC-I and enhances NK lysis. Cell. Immunol. 180:55.
30. O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275.
31. D'Andrea, A., M. Aste Amezaga, N. M. Valiante, X. Ma, M. Kublin, and G. Trinchieri. 1993. Interleukin-10 inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1041.
32. Ulrich, S. E. 1994. Mechanism involved in the systemic suppression of antigen presenting cell function by UV irradiation: keratocyle-derived IL-10 modulates antigen presenting cell function of splenic adherent cells. J. Immunol. 154:3410.
33. Matsuda, M., F. Salazar, M. Petersson, G. Masucci, J. Hansson, P. Pisa, Q.-J. Zhang, M. G. Masucci, and R. Kiessling. 1994. Interleukin-10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class-I expression. J. Exp. Med. 180:2371.
34. Salazar-Onfray, F., M. Petersson, F. Franksson, M. Matsuda, T. Blankenstein, K. Karre, and R. Kiessling. 1995. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK sensitive phenotype with low but peptide-inducible MHC-I expression. J. Immunol. 154:6291.
35. Takenaka, H., S. Maruo, N. Yamamoto, M. Wysocka, S. Ono, M. Kobayashi, H. Yogita, K. Okumura, T. Hamaoka, G. Trinchieri, and H. Fujiwara. 1997. Regulation of T cell dependent and independent IL-12 production by the three Th2 type cytokines IL-10, IL-6 and IL-4. J. Leukoc. Biol. 61:80.
36. Aruga, A., E. Aruga, K. Tanigawa, D. K. Bishop, V. K. Sondak, and A. E Chang. 1997. Type 1 versus type 2 cytokine release by vβ T cells subpopulations determines in vivo anti tumor reactivity. J. Immunol. 159:664.
37. Tada, T., Y. Asano, and K. Sano. 1989. Present understanding of suppressor T cells. Res. Immunol. 140:291.
38. North, R. J. 1985. Down-regulation of the anti-tumor immune response. Adv. Cancer Res. 45:1.
39. Hengst, J. C. D., M. B. Mokyr, and S. Dray. 1981. Cooperation between cyclophosphamide tumoricidal activity and host anti-tumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res. 41:2163.
40. Berd, D., J. J. Mastrangelo, P. F. Engstrom, A. Paul, and H. Maguire. 1982. Augmentation of the human immune response by cyclophosphamide. Cancer Res. 42:4862.
41. + T cells to enhance priming for interferon γ production and diminishes Interleukin-4 inhibition of such priming. Proc Natl. Acad. Sci. USA 1990:10188.
42. + Immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin-2 production. J. Exp. Med. 188:287.
43. + T-cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 389:737.
44. + T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. J. Exp. Med. 188:1875.
45. + T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J. Exp. Med. 188:1883.